About Azafaros

Azafaros was founded in 2018 by a team of experienced industry professionals and scientists and aspires to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today.

This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program toward first-in-man studies while further expanding its drug discovery efforts into other rare metabolic diseases.